Circulating interleukin 16 (IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): A novel serological marker of disease activity

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 57, Issue 9, 2002, Pages 815-820

  Frezzolini, A ^a   Paradisi, M ^a   Zaffiro, A ^a   Provini, A ^a   Cadoni, S ^a   Ruffelli, M ^a   De Pita O ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Atopic eczema dermatitis syndrome; Chemokines; Disease activity; IL 16

Indexed keywords

CD30 ANTIGEN; CHEMOKINE; EOTAXIN; INTERLEUKIN 16; RANTES; BETA CHEMOKINE; BIOLOGICAL MARKER; EOSINOPHIL CHEMOTACTIC FACTOR; IMMUNOGLOBULIN E;

ARTICLE; ATOPIC DERMATITIS; ATOPIC ECZEMA DERMATITIS SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; ENZYME ASSAY; HUMAN; IMMUNE RESPONSE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCORING SYSTEM; SEROLOGY; ASTHMA; BLOOD; CHILD; INFANT; SYNDROME;

ANTIGENS, CD30; ASTHMA; BIOLOGICAL MARKERS; CHEMOKINES, CC; CHEMOTACTIC FACTORS, EOSINOPHIL; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; HUMAN; IMMUNOGLOBULIN E; INFANT; INTERLEUKIN-16; RANTES; SYNDROME; HUMANS;

EID: 0036724863     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2002.23687.x     Document Type: Article

References (37)

1. Atopic dermatitis: New insights and opportunities for therapeutic intervention
2. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force
3. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis
4. Cellular and immunologic mechanisms in atopic dermatitis
5. Chemokines and leukocyte traffic
6. Chemokines: Immunology's high impact factors
7. Chemokines and disease
8. Chemokine RANTES in atopic dermatitis
9. The C-C chemokines, RANTES and eotaxin, in atopic dermatitis
10. Enhanced expression of eotaxin and CCR3 in atopic dermatitis
11. Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children
12. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis
13. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis
14. A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin
15. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity
16. Signaling and functional properties of interleukin-16
17. Interleukin-16
18. Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma
19. Increased expression of the chemoattractant cytokines eotaxin, monocyte chemotactic protein-4, and interleukin-16 in induced sputum in asthmatic patients
20. Circulating interleukin-16 in systemic lupus erythematosus
21. A possible pathogenic role of CD8+ T cells and their derived cytokine, IL-16, in SLE
22. Interleukin 16 expression in relation to disease activity in rheumatoid arthritis
23. Interleukin 16: Implications for CD4 functions and HIV-1 progression
24. Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis
25. Severity scoring of atopic dermatitis: The SCORAD Index
26. Chemoattractant receptors expressed on type 2 T cells and their role in disease
27. Chemokines, chemokine receptors and allergy
28. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines
29. Inducible expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3 alpha/CCL20 by epidermal keratinocytes and its role in atopic dermatitis
30. The eotaxins in asthma and allergic inflammation: Implications for therapy
31. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES
32. Soluble CD30 in pediatric patients with atopic dermatitis
33. Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: A possible new immune intervention
34. Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: Correlation with disease activity
35. Serum levels of soluble stem cell factor and soluble KIT are elevated in patients with atopic dermatitis and correlate with the disease severity
36. Soluble E-selectin correlates with disease activity in cyclosporin A-treated patients with atopic dermatitis
37. Engagement of the FcεRI stimulates the production of IL-16 in Langerhans cell-like dendritic cells